Canós Molinos J, Muñoz-López F
Servicio de Inmunología y Alergia Pediátrica, Hospital Clínico, Facultad de Medicina, Barcelona, Spain.
Allergol Immunopathol (Madr). 1997 Jan-Feb;25(1):10-7.
Immunotherapy is an empirical treatment with proven clinical efficacy. Different results have been found when comparing the levels of the subclasses for immunoglobulin G and the clinical development during immunotherapy. A follow up study was carried out for one year on the IgG subclasses in 21 asthmatic children of both sexes and ages ranging from 8 to 11 years. The children were sensitized to Dermatophagoides Pteronyssinus and had undergone immunotherapy treatment. The clinical and analytical evaluation were carried out before treatment was started and later every four months. In terms of clinical evolution, the children were separated into two groups. The levels of IgG1 show different evolution in terms of a good or not good clinical evolution with a p of 0.056. Levels of IgG2 showed no differences. IgG3 shows a disorderly distribution. A continuous increase in IgG4 levels was observed from the start of immunotherapy though no differences in terms of clinical evolution were recorded. With the results obtained, it can be concluded that the gradual increase of IgG4 together with an early rise in IgG1 levels are related to the clinical efficacy of immunotherapy.
免疫疗法是一种具有已证实临床疗效的经验性治疗方法。在比较免疫球蛋白G亚类水平与免疫疗法期间的临床进展时发现了不同的结果。对21名年龄在8至11岁之间的男女哮喘儿童的IgG亚类进行了为期一年的随访研究。这些儿童对屋尘螨过敏,并接受了免疫疗法治疗。在治疗开始前以及之后每四个月进行临床和分析评估。就临床进展而言,将儿童分为两组。IgG1水平在临床进展良好或不佳方面显示出不同的变化,p值为0.056。IgG2水平无差异。IgG3显示出无序分布。从免疫疗法开始就观察到IgG4水平持续升高,尽管在临床进展方面未记录到差异。根据获得的结果,可以得出结论,IgG4的逐渐增加以及IgG1水平的早期升高与免疫疗法的临床疗效有关。